Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Find the Native Culinary Customs: Local Flavors - 2The most effective method to Comprehend the Variables Affecting Medical attendant Pay rates
- 3This Asian country is the next hot travel destination, and this is one of its best hotels
- 4Manual for Instructive Application for Youngsters
- 5Audits of Espresso Types: Which Mix Is for You?
- Bolsonaro discharged from hospital and placed under house arrest
- Must-Have Cooking Machine in Your Kitchen
- Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
- Language Learning Applications for Voyagers
- Argentina joins NASA’s moon return with microsatellite testing GPS beyond Earth
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- If everyone on Earth sat in the ocean at once, how much would sea level rise?
- Astronomers now say the moon is eating up molecules from Earth’s atmosphere
- Taylor Swift changes 2 song lyrics on 'Reputation' on the night of her Eras tour documentary premiere
